MedTrace Logo

Ropinirole in the Treatment of Bipolar Depression

NCT00314821 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-04-18

No results posted yet for this study

Summary

To demonstrate efficacy and safety of Requip in in treating bipolar depression.

Conditions

Interventions

DRUG

ropinirole

Sponsors & Collaborators

  • Emory University

    collaborator OTHER

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Cambridge Health Alliance

    lead OTHER

Principal Investigators

  • Robert T Dunn, MD,PhD · Cambridge Health Alliance

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2007-06-01
Completion
2008-03-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00314821 on ClinicalTrials.gov